Abstract
Purpose :
Clinicians increasingly use spectral-domain optical coherence tomography (SD-OCT) to diagnose and follow neovascular age-related macular degeneration (nAMD). The purpose of this analysis of pooled data from HARBOR was to evaluate rates of fibrosis from choroidal neovascularization (CNV) based on SD-OCT classification.
Methods :
SD-OCT scans from the phase 3 HARBOR trial (NCT00891735) of ranibizumab in patients with nAMD were reread by Doheny Image Reading and Research Laboratory, and CNV was classified as type 1, 2, and/or 3. Month 24 fibrosis status/location by baseline CNV type were evaluated using pooled observed data.
Results :
At month 24, fibrosis was present in 31% (67/216) of eyes with type 1 lesions, 53% (176/332) with type 2 lesions, 45% (120/264) with mixed type 1/2 lesions, and 33% (17/51) with any type 3 lesions (overall P < 0.0001; Figure 1). Of those eyes with subretinal fibrosis, the majority had subfoveal involvement at month 24 (% patients for each lesion type: type 1, 75%; type 2, 78%; mixed type 1/2, 73%; type 3, 65%). Results were generally similar when stratified by treatment regimen (monthly vs pro re nata [as-needed]; Figure 2).
Conclusions :
These findings demonstrate that eyes with type 2 CNV lesions had higher rates of fibrosis at month 24 than those with other lesion types.
This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.